Ultrasound-Guided Thoracic Paravertebral Block Versus External Oblique Intercostal Block for Postoperative Analgesia After Open Radical Nephrectomy: A Randomised Controlled Trial
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Hacettepe University
- Enrollment
- 98
- Locations
- 2
- Primary Endpoint
- Postoperative Pain Score
Study Overview
Brief Summary
This study aims to compare the effects of external oblique intercostal block versus paravertebral block on postoperative pain and complications in patients undergoing open nephrectomy.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 18 Years to 90 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Aged 18 to 90 years
- •Scheduled for elective open radical nephrectomy for renal cell carcinoma
- •ASA classification I-III
- •Mini-Mental State Examination score ≥24
- •Provided written informed consent
Exclusion Criteria
- •Neuropathy
- •Hepatic failure
- •Coagulopathy
- •Local anesthetic allergy
- •Mini-Mental State Examination score <24
- •Refusal to participate
Arms & Interventions
Paravertebral block
Patients scheduled to undergo thoracic paravertebral block will receive an injection of 20 ml of 0.25% bupivacaine hydrochloride into the paravertebral space between the parietal pleura and the costotransverse ligament using a block needle under ultrasound guidance.
Intervention: Bupivacaine (Drug)
Paravertebral block
Patients scheduled to undergo thoracic paravertebral block will receive an injection of 20 ml of 0.25% bupivacaine hydrochloride into the paravertebral space between the parietal pleura and the costotransverse ligament using a block needle under ultrasound guidance.
Intervention: morphine (Drug)
Paravertebral block
Patients scheduled to undergo thoracic paravertebral block will receive an injection of 20 ml of 0.25% bupivacaine hydrochloride into the paravertebral space between the parietal pleura and the costotransverse ligament using a block needle under ultrasound guidance.
Intervention: paracetamol (Drug)
Paravertebral block
Patients scheduled to undergo thoracic paravertebral block will receive an injection of 20 ml of 0.25% bupivacaine hydrochloride into the paravertebral space between the parietal pleura and the costotransverse ligament using a block needle under ultrasound guidance.
Intervention: Diclofenac (Drug)
External Oblique Intercostal Block
Patients scheduled to undergo an external oblique intercostal block will receive an injection of 30 ml of 0.25% bupivacaine hydrochloride between the external oblique muscle and the intercostal muscle at the level of the 6th rib, using a block needle under ultrasound guidance.
Intervention: Bupivacaine (Drug)
External Oblique Intercostal Block
Patients scheduled to undergo an external oblique intercostal block will receive an injection of 30 ml of 0.25% bupivacaine hydrochloride between the external oblique muscle and the intercostal muscle at the level of the 6th rib, using a block needle under ultrasound guidance.
Intervention: morphine (Drug)
External Oblique Intercostal Block
Patients scheduled to undergo an external oblique intercostal block will receive an injection of 30 ml of 0.25% bupivacaine hydrochloride between the external oblique muscle and the intercostal muscle at the level of the 6th rib, using a block needle under ultrasound guidance.
Intervention: paracetamol (Drug)
External Oblique Intercostal Block
Patients scheduled to undergo an external oblique intercostal block will receive an injection of 30 ml of 0.25% bupivacaine hydrochloride between the external oblique muscle and the intercostal muscle at the level of the 6th rib, using a block needle under ultrasound guidance.
Intervention: Diclofenac (Drug)
Outcomes
Primary Outcomes
Postoperative Pain Score
Time Frame: Up to 24 hours after surgery
Pain intensity measured using Visual Analog Scale at rest. (Visual Analog Scale ranging from 0 = no pain to 10 = worst pain imaginable; higher scores indicate worse pain).
Secondary Outcomes
No secondary outcomes reported
Investigators
Almıla Gulsun Pamuk
Associate Professor
Hacettepe University